Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas.
Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori describe this month in BMC Biology experiments indicating a novel role of the adaptor protein p130Cas in sensitivity to apoptosis induced not only by proteasome inhibitors but also by the unrelated drug doxorubicin.
The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. Dharminder_Chauhan@dfci.harvard.edu
Dharminder
D
Chauhan
Kenneth C
KC
Anderson
D000818:Animals; D050719:Crk-Associated Substrate Protein / Q000378:metabolism*; D005347:Fibroblasts / Q000201:enzymology*; D061988:Proteasome Inhibitors
D050719:Crk-Associated Substrate Protein; D061988:Proteasome Inhibitors